Posted: 27 June 2024 Emerging treatments for muscle, kidney and heart diseases were among the stem cell projects showcased at the Annual Scientific Meeting of the Novo Nordisk Foundation Center for Stem Cell Medicine (reNEW) in Melbourne. reNEW is…
Posted: 27 June 2024 Optiscan is excited to be included in Stockhead regarding the unveiling of InVue™ – our next gen microscopic medical imaging device for precision surgery. The article focuses on how InVue™ broadens Optiscan’s product portfolio in the surgical…
Posted: 27 June 2024 MTPConnect, Australia’s life sciences innovation accelerator, and Biocom California have committed to working closely together to support the growth of life sciences companies, with the signing today of a Memorandum of Understanding at the 2024…
Posted: 27 June 2024 Over the last three and a half years, REDI has delivered training, mentoring and industry placements to more than 8,400 participants across Australia, nearly double the original target. The report – ‘Improving workforce skills in…
Posted: 27 June 2024 Brandon Capital, Australasia’s leading life sciences venture capital firm, today announced the launch of its sixth fund, Brandon Capital Fund VI, with an initial close at A$270 million (US$180 million). This new fund will…
Posted: 27 June 2024 A new test promises to predict whether someone will get dementia, almost a decade before diagnosis. An international research team, including Associate Professor Adeel Razi, from Melbourne’s Monash University, have developed a new method…
Posted: 27 June 2024 A scientific team from the Yong Loo Lin School of Medicine at the National University of Singapore (NUS Medicine) and Monash University has engineered a COVID-19 vaccine that induced – in pre-clinical models –…
Posted: 27 June 2024 A novel combination of two cancer drugs has shown great potential as a future treatment for patients with acute myeloid leukaemia (AML), one of the most common types of blood cancers. A new study by WEHI…
Posted: 27 June 2024 Participants in clinical trials get early access to these potentially life-saving new therapies, while at the same time advancing medical knowledge. More broadly, clinical trial activity contributes to the development of a thriving research…
Posted: 27 July 2024 Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to share the power of the geneType test in identifying risk…
Posted: 27 June 2024 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces topline results from the TACTI-003 (KEYNOTE-PNC-34) Phase IIb trial…
Posted: 27 June 2024 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune diseases, today announces a License Agreement with Cardiff University granting the Company…